We are very pleased to announce that latest results on Metavac®-RSV, a bivalent intranasal vaccine candidate against human Metapneumovirus (hMPV) and Respiratory Syncytial Virus (RSV), has been published in npj Vaccines.
Developed by the International Research Laboratory RESPIVIR France – Canada (Université Laval, Québec, Canada & Université Claude Bernard, Lyon, France), Metavac®-RSV's efficacy was validated in a second animal model showing the high efficacy of our intranasal vaccine candidate. The in vivo testing in cotton rats was independently performed by Sigmovir Biosystems, Inc and funded by the U.S. National Institute of Allergy and Infectious Diseases (NIAID of the NIH, under contract # HHSN272201700028I / 75N93023F00001 / A88HHSN272201700028I/75N93023F00001/A88).
The results show full protection against hMPV et RSV and confirm the results obtained in mice in a previous experiment published in npj vaccine in June 2024.
This is a critical step forward for Vaxxel, as this study represents an independent validation of the preclinical efficacy of Metavac®-RSV in a second animal model detailing the high efficacy of our intranasal vaccine candidate.
Beyond in vivo efficacy, the publication also details our success in establishing an efficient, scalable upstream production process in a 2L bioreactor, proving the industrial viability of our candidate for future clinical trials and commercialization.
With this strong external validation and a clear path to manufacturing, Vaxxel is now advancing toward a Phase I clinical trial and is currently raising €8m to bring this promising vaccine to the clinic.
To learn more, we invite you to visit the publication website and read the full article: https://www.nature.com/articles/s41541-025-01231-9
